Skip to main content

Table 1 Patient clinical and pathological characteristics

From: Longitudinal autoantibody responses against tumor-associated antigens decrease in breast cancer patients according to treatment modality

Patients with Breast Cancer

N = 200

 Age: Mean (SD)

58.9 (11.4)

 White Race: n (%)

193 (97%)

 BMI [kg/m2]: Mean (SD)

29.7 (6.6)

Smoking Status: n (%)

 Current

22 (11%)

 Never

120 (60%)

 Past

58 (29%)

 Family History Yes: n (%)

114 (58%)

Tumor Type: n (%)

 Invasive

148 (74%)

 in situ

52 (26%)

Tumor Max Dimension [cm]: n (%)

  ≤ 1

66 (36%)

  > 1 to ≤2

65 (35%)

  > 2

53 (29%)

Histology: n (%)

 Ductal and Lobular

3 (2%)

 Ductal

173 (87%)

 Lobular

21 (11%)

 Other

2 (1%)

 ER Positive: n (%)

171 (86%)

 PR Positive: n (%)

147 (74%)

HER2 Amplification: n (%)

 Negative

132 (66%)

 Positive

15 (8%)

 Unknown

53 (27%)

 Triple Negative: n (%)

18 (12%)

 Lymph Node Involvement: n (%)

47 (24%)

Matched Healthy Controls

N = 200

 Age: Mean (SD)

58.8 (11.3)

 White Race: n (%)

192 (97%)

 BMI [kg/m2]: Mean (SD)

27.1 (5.5)

Smoking Status: n (%)

 Current

7 (4%)

 Never

125 (63%)

 Past

67 (34%)